Top

Cancer & Metabolism

Published in:

Open Access 01-12-2013 | Research

Ets-1 global gene expression profile reveals associations with metabolism and oxidative stress in ovarian and breast cancers

Authors: Meghan L Verschoor, Chris P Verschoor, Gurmit Singh

Published in: Cancer & Metabolism | Issue 1/2013

Abstract

Background

The Ets-1 proto-oncogene is frequently upregulated in cancer cells, with known involvement in cancer angiogenesis, metastasis, and more recently energy metabolism. In this study we have performed various bioinformatic analyses on existing microarray data to further clarify the role of Ets-1 in ovarian cancer, and validated these results with functional assays.

Methods

Functional pathway analyses were conducted on existing microarray data comparing 2008 and 2008-Ets1 ovarian cancer cells. Methods included over-representation analysis, functional class scoring and pathway topology, and network representations were visualized in Cytoscape. Oxidative stress regulation was examined in ovarian cancer cells by measuring protein expression and enzyme activity of glutathione peroxidases, as well as intracellular reactive oxygen species using dichlorofluorescin fluorescence. A stable Ets-1 knockdown MDA-MB-231 cell line was created using short hairpin RNA, and glycolytic dependence of these cells was measured following treatment with 2-deoxy-D-glucose and Hoechst nuclear staining to determine cell number. High-resolution respirometry was performed to measure changes in basal oxygen flux between MDA-MB-231 cells and MDA-Ets1KD variants.

Results

Enrichments in oxidoreductase activity and various metabolic pathways were observed upon integration of the different analyses, suggesting that Ets-1 is important in their regulation. As oxidative stress is closely associated with these pathways, we functionally validated our observations by showing that Ets-1 overexpression resulted in decreased reactive oxygen species with increased glutathione peroxidase expression and activity, thereby regulating cellular oxidative stress. To extend our findings to another cancer type, we developed an Ets-1 knockdown breast cancer cell model, which displayed decreased glycolytic dependence and increased oxygen consumption following Ets-1 knockdown confirming our earlier findings.

Conclusions

Collectively, this study confirms the important role of Ets-1 in the regulation of cancer energy metabolism in ovarian and breast cancers. Furthermore, Ets-1 is a key regulator of oxidative stress in ovarian cancer cells by mediating alterations in glutathione antioxidant capacity.

Available only for authorised users

Leprince D, Gegonne A, Coll J, de Taisne C, Schneeberger A, Lagrou C, Stehelin D: A putative second cell-derived oncogene of the avian leukaemia retrovirus E26. Nature. 1983, 306 (5941): 395-397. 10.1038/306395a0.CrossRefPubMed

Oikawa T, Yamada T: Molecular biology of the Ets family of transcription factors. Gene. 2003, 303: 11-34.CrossRefPubMed

Seth A, Watson DK: ETS transcription factors and their emerging roles in human cancer. Eur J Cancer. 2005, 41 (16): 2462-2478. 10.1016/j.ejca.2005.08.013.CrossRefPubMed

Baldus CD, Liyanarachchi S, Mrozek K, Auer H, Tanner SM, Guimond M, Ruppert AS, Mohamed N, Davuluri RV, Caligiuri MA, Bloomfield CD, de la Chapelle A: Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci U S A. 2004, 101 (11): 3915-3920. 10.1073/pnas.0400272101.PubMedCentralCrossRefPubMed

Foos G, Garcia-Ramirez JJ, Galang CK, Hauser CA: Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular transformation. J Biol Chem. 1998, 273 (30): 18871-18880. 10.1074/jbc.273.30.18871.CrossRefPubMed

Foos G, Hauser CA: Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness. Oncogene. 2000, 19 (48): 5507-5516. 10.1038/sj.onc.1203946.CrossRefPubMed

Santoro A, Maggio A, Carbone P, Mirto S, Caronia F, Acuto S: Amplification of ETS2 oncogene in acute nonlymphoblastic leukemia with t(6;21;18). Cancer Genet Cytogenet. 1992, 58 (1): 71-75. 10.1016/0165-4608(92)90137-W.CrossRefPubMed

Sapi E, Flick MB, Rodov S, Kacinski BM: Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells. Cancer Res. 1998, 58 (5): 1027-1033.PubMed

Sementchenko VI, Schweinfest CW, Papas TS, Watson DK: ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene. 1998, 17 (22): 2883-2888. 10.1038/sj.onc.1202220.CrossRefPubMed

10.

Poppe B, Vandesompele J, Schoch C, Lindvall C, Mrozek K, Bloomfield CD, Beverloo HB, Michaux L, Dastugue N, Herens C, Yigit N, De Paepe A, Hagemeijer A, Speleman F: Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood. 2004, 103 (1): 229-235. 10.1182/blood-2003-06-2163.CrossRefPubMed

11.

Kurpios NA, Sabolic NA, Shepherd TG, Fidalgo GM, Hassell JA: Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia. 2003, 8 (2): 177-190. 10.1023/A:1025948823955.CrossRefPubMed

12.

Shepherd TG, Kockeritz L, Szrajber MR, Muller WJ, Hassell JA: The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Curr Biol. 2001, 11 (22): 1739-1748. 10.1016/S0960-9822(01)00536-X.CrossRefPubMed

13.

Ghadersohi A, Sood AK: Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clin Cancer Res. 2001, 7 (9): 2731-2738.PubMed

14.

Dittmer J: The biology of the Ets1 proto-oncogene. Mol Cancer. 2003, 2: 29-10.1186/1476-4598-2-29.PubMedCentralCrossRefPubMed

15.

Graves BJ, Petersen JM: Specificity within the ets family of transcription factors. Adv Cancer Res. 1998, 75: 1-55.CrossRefPubMed

16.

Verschoor ML, Wilson LA, Singh G: Mechanisms associated with mitochondrial-generated reactive oxygen species in cancer. Can J Physiol Pharmacol. 2010, 88 (3): 204-219. 10.1139/Y09-135.CrossRefPubMed

17.

Buggy Y, Maguire TM, McGreal G, McDermott E, Hill AD, O’Higgins N, Duffy MJ: Overexpression of the Ets-1 transcription factor in human breast cancer. Br J Cancer. 2004, 91 (7): 1308-1315. 10.1038/sj.bjc.6602128.PubMedCentralCrossRefPubMed

18.

Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, Ben-Baruch G, Bryne M, Nesland JM: Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res. 2001, 7 (3): 551-557.PubMed

19.

Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Trope CG, Kristensen GB, Bryne M, Reich R: Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Am J Surg Pathol. 2001, 25 (12): 1493-1500. 10.1097/00000478-200112000-00004.CrossRefPubMed

20.

Fujimoto J, Aoki I, Toyoki H, Khatun S, Sato E, Sakaguchi H, Tamaya T: Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers. Oncology. 2004, 66 (5): 420-428. 10.1159/000079491.CrossRefPubMed

21.

Katayama S, Nakayama T, Ito M, Naito S, Sekine I: Expression of the ets-1 proto-oncogene in human breast carcinoma: differential expression with histological grading and growth pattern. Histol Histopathol. 2005, 20 (1): 119-126.PubMed

22.

Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, Beex LV, Sweep CG: Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene. 2002, 21 (55): 8506-8509. 10.1038/sj.onc.1206040.CrossRefPubMed

23.

Alipov G, Nakayama T, Ito M, Kawai K, Naito S, Nakashima M, Niino D, Sekine I: Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology. 2005, 46 (2): 202-208. 10.1111/j.1365-2559.2005.02059.x.CrossRefPubMed

24.

Chang XZ, Yu J, Zhang XH, Yin J, Wang T, Cao XC: Enhanced expression of trophinin promotes invasive and metastatic potential of human gallbladder cancer cells. J Cancer Res Clin Oncol. 2009, 135 (4): 581-590. 10.1007/s00432-008-0492-1.CrossRefPubMed

25.

Sasaki H, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, Kaji M, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y: Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J Surg Res. 2001, 101 (2): 242-247. 10.1006/jsre.2001.6279.CrossRefPubMed

26.

Saeki H, Oda S, Kawaguchi H, Ohno S, Kuwano H, Maehara Y, Sugimachi K: Concurrent overexpression of Ets-1 and c-Met correlates with a phenotype of high cellular motility in human esophageal cancer. Int J Cancer. 2002, 98 (1): 8-13. 10.1002/ijc.10163.CrossRefPubMed

27.

Ghosh S, Basu M, Roy SS: ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3. J Biol Chem. 2012, 287 (18): 15001-15015. 10.1074/jbc.M111.284034.PubMedCentralCrossRefPubMed

28.

Lin Z, Liu Y, Sun Y, He X: Expression of Ets-1, Ang-2 and maspin in ovarian cancer and their role in tumor angiogenesis. J Exp Clin Cancer Res. 2011, 30: 31-10.1186/1756-9966-30-31.PubMedCentralCrossRefPubMed

29.

Okuducu AF, Zils U, Michaelis SA, Michaelides S, von Deimling A: Ets-1 is up-regulated together with its target gene products matrix metalloproteinase-2 and matrix metalloproteinase-9 in atypical and anaplastic meningiomas. Histopathology. 2006, 48 (7): 836-845. 10.1111/j.1365-2559.2006.02432.x.CrossRefPubMed

30.

Park YH, Jung HH, Ahn JS, Im YH: Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. Biochem Biophys Res Commun. 2008, 377 (2): 389-394. 10.1016/j.bbrc.2008.09.135.CrossRefPubMed

31.

Sementchenko VI, Watson DK: Ets target genes: past, present and future. Oncogene. 2000, 19 (55): 6533-6548. 10.1038/sj.onc.1204034.CrossRefPubMed

32.

Verschoor ML, Wilson LA, Verschoor CP, Singh G: Ets-1 regulates energy metabolism in cancer cells. PLoS One. 2010, 5 (10): e13565-10.1371/journal.pone.0013565.PubMedCentralCrossRefPubMed

33.

Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS, Huang WL, Zeng YX, Shao JY: miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 2011, 71 (10): 3552-3562. 10.1158/0008-5472.CAN-10-2435.CrossRefPubMed

34.

Andrews PA, Albright KD: Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res. 1992, 52 (7): 1895-1901.PubMed

35.

da Huang W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009, 4 (1): 44-57.CrossRefPubMed

36.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005, 102 (43): 15545-15550. 10.1073/pnas.0506580102.PubMedCentralCrossRefPubMed

37.

Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003, 34 (3): 267-273. 10.1038/ng1180.CrossRefPubMed

38.

Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T: Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011, 27 (3): 431-432. 10.1093/bioinformatics/btq675.PubMedCentralCrossRefPubMed

39.

Assenov Y, Ramirez F, Schelhorn SE, Lengauer T, Albrecht M: Computing topological parameters of biological networks. Bioinformatics. 2008, 24 (2): 282-284. 10.1093/bioinformatics/btm554.CrossRefPubMed

40.

Wu G, Feng X, Stein L: A human functional protein interaction network and its application to cancer data analysis. Genome Biol. 2010, 11 (5): R53-10.1186/gb-2010-11-5-r53.PubMedCentralCrossRefPubMed

41.

Merico D, Isserlin R, Stueker O, Emili A, Bader GD: Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010, 5 (11): e13984-10.1371/journal.pone.0013984.PubMedCentralCrossRefPubMed

42.

Bader GD, Hogue CW: An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003, 4: 2-10.1186/1471-2105-4-2.PubMedCentralCrossRefPubMed

43.

Schneider CA, Rasband WS, Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012, 9 (7): 671-675. 10.1038/nmeth.2089.CrossRefPubMed

44.

Wilson LA, Yamamoto H, Singh G: Role of the transcription factor Ets-1 in cisplatin resistance. Mol Cancer Ther. 2004, 3 (7): 823-832.PubMed

45.

Khatri P, Sirota M, Butte AJ: Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput Biol. 2012, 8 (2): e1002375-10.1371/journal.pcbi.1002375.PubMedCentralCrossRefPubMed

46.

Adam M, Schmidt D, Wardelmann E, Wernert N, Albers P: Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. Eur Urol. 2003, 44 (3): 329-336. 10.1016/S0302-2838(03)00262-8.CrossRefPubMed

47.

Behrens P, Mathiak M, Mangold E, Kirdorf S, Wellmann A, Fogt F, Rothe M, Florin A, Wernert N: Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1 and −9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers. Int J Cancer. 2003, 107 (2): 183-188. 10.1002/ijc.11336.CrossRefPubMed

48.

Behrens P, Rothe M, Wellmann A, Krischler J, Wernert N: The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol. 2001, 194 (1): 43-50. 10.1002/path.844.CrossRefPubMed

49.

Bolon I, Gouyer V, Devouassoux M, Vandenbunder B, Wernert N, Moro D, Brambilla C, Brambilla E: Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Am J Pathol. 1995, 147 (5): 1298-1310.PubMedCentralPubMed

50.

Hahne JC, Fuchs T, El Mustapha H, Okuducu AF, Bories JC, Wernert N: Expression pattern of matrix metalloproteinase and TIMP genes in fibroblasts derived from Ets-1 knock-out mice compared to wild-type mouse fibroblasts. Int J Mol Med. 2006, 18 (1): 153-159.PubMed

51.

Hahne JC, Okuducu AF, Kaminski A, Florin A, Soncin F, Wernert N: Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene. 2005, 24 (34): 5384-5388. 10.1038/sj.onc.1208761.CrossRefPubMed

52.

Hahne JC, Okuducu AF, Sahin A, Fafeur V, Kiriakidis S, Wernert N: The transcription factor ETS-1: its role in tumour development and strategies for its inhibition. Mini Rev Med Chem. 2008, 8 (11): 1095-1105. 10.2174/138955708785909934.CrossRefPubMed

53.

Khatun S, Fujimoto J, Toyoki H, Tamaya T: Clinical implications of expression of ETS-1 in relation to angiogenesis in ovarian cancers. Cancer Sci. 2003, 94 (9): 769-773. 10.1111/j.1349-7006.2003.tb01517.x.CrossRefPubMed

54.

Lefter LP, Dima S, Sunamura M, Furukawa T, Sato Y, Abe M, Chivu M, Popescu I, Horii A: Transcriptional silencing of ETS-1 efficiently suppresses angiogenesis of pancreatic cancer. Cancer Gene Ther. 2009, 16 (2): 137-148. 10.1038/cgt.2008.65.CrossRefPubMed

55.

Nakada M, Yamashita J, Okada Y, Sato H: Ets-1 positively regulates expression of urokinase-type plasminogen activator (uPA) and invasiveness of astrocytic tumors. J Neuropathol Exp Neurol. 1999, 58 (4): 329-334. 10.1097/00005072-199904000-00003.CrossRefPubMed

56.

Rothhammer T, Hahne JC, Florin A, Poser I, Soncin F, Wernert N, Bosserhoff AK: The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci. 2004, 61 (1): 118-128. 10.1007/s00018-003-3337-8.CrossRefPubMed

57.

Sahin A, Velten M, Pietsch T, Knuefermann P, Okuducu AF, Hahne JC, Wernert N: Inactivation of Ets 1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and mmp-9 expression. Int J Mol Med. 2005, 15 (5): 771-776.PubMed

58.

Sahin A, Vercamer C, Kaminski A, Fuchs T, Florin A, Hahne JC, Mattot V, Pourtier-Manzanedo A, Pietsch T, Fafeur V, Wernert N: Dominant-negative inhibition of Ets 1 suppresses tumor growth, invasion and migration in rat C6 glioma cells and reveals differentially expressed Ets 1 target genes. Int J Oncol. 2009, 34 (2): 377-389.PubMed

59.

Sakaguchi H, Fujimoto J, Aoki I, Toyoki H, Sato E, Tamaya T: Expression of E26 transformation specific (ETS-1) related to angiogenesis in ovarian endometriosis. Fertil Steril. 2004, 82 (2): 507-510. 10.1016/j.fertnstert.2004.02.103.CrossRefPubMed

60.

Shimizu S, Kageyama M, Yasuda M, Sasaki D, Naito S, Yamamoto T, Kiuchi Y: Stimulation of in vitro angiogenesis by nitric oxide through the induction of transcription factor ETS-1. Int J Biochem Cell Biol. 2004, 36 (1): 114-122. 10.1016/S1357-2725(03)00170-5.CrossRefPubMed

61.

Watabe T, Yoshida K, Shindoh M, Kaya M, Fujikawa K, Sato H, Seiki M, Ishii S, Fujinaga K: The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer. 1998, 77 (1): 128-137. 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9.CrossRefPubMed

62.

Wernert N, Stanjek A, Kiriakidis S, Hugel A, Jha HC, Mazitschek R, Giannis A: Inhibition of angiogenesis in vivo by ets-1 antisense oligonucleotides-inhibition of Ets-1 transcription factor expression by the antibiotic fumagillin. Angew Chem Int Ed Engl. 1999, 38 (21): 3228-3231. 10.1002/(SICI)1521-3773(19991102)38:21<3228::AID-ANIE3228>3.0.CO;2-8.CrossRefPubMed

63.

Yasuda M, Ohzeki Y, Shimizu S, Naito S, Ohtsuru A, Yamamoto T, Kuroiwa Y: Stimulation of in vitro angiogenesis by hydrogen peroxide and the relation with ETS-1 in endothelial cells. Life Sci. 1999, 64 (4): 249-258.CrossRefPubMed

64.

Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, Oettgen P: Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest. 2005, 115 (9): 2508-2516. 10.1172/JCI24403.PubMedCentralCrossRefPubMed

65.

Oda N, Abe M, Sato Y: ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3. J Cell Physiol. 1999, 178 (2): 121-132. 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.0.CO;2-F.CrossRefPubMed

66.

Liu Y: Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 2006, 9 (3): 230-234. 10.1038/sj.pcan.4500879.CrossRefPubMed

67.

Martinez-Orozco R, Navarro-Tito N, Soto-Guzman A, Castro-Sanchez L, Perez Salazar E: Arachidonic acid promotes epithelial-to-mesenchymal-like transition in mammary epithelial cells MCF10A. Eur J Cell Biol. 2010, 89 (6): 476-488. 10.1016/j.ejcb.2009.12.005.CrossRefPubMed

68.

Chang NW, Wu CT, Chen DR, Yeh CY, Lin C: High levels of arachidonic acid and peroxisome proliferator-activated receptor-alpha in breast cancer tissues are associated with promoting cancer cell proliferation. J Nutr Biochem. 2013, 24 (1): 274-281. 10.1016/j.jnutbio.2012.06.005.CrossRefPubMed

69.

Wen ZH, Su YC, Lai PL, Zhang Y, Xu YF, Zhao A, Yao GY, Jia CH, Lin J, Xu S, Wang L, Wang XK, Liu AL, Jiang Y, Dai YF, Bai XC: Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis. Oncogene. 2013, 32 (2): 160-170. 10.1038/onc.2012.47.CrossRefPubMed

70.

Cho KJ, Seo JM, Kim JH: Bioactive lipoxygenase metabolites stimulation of NADPH oxidases and reactive oxygen species. Mol Cells. 2011, 32 (1): 1-5. 10.1007/s10059-011-1021-7.PubMedCentralCrossRefPubMed

71.

Brigelius-Flohe R, Kipp A: Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta. 2009, 1790 (11): 1555-1568. 10.1016/j.bbagen.2009.03.006.CrossRefPubMed

72.

Gouaze V, Mirault ME, Carpentier S, Salvayre R, Levade T, Andrieu-Abadie N: Glutathione peroxidase-1 overexpression prevents ceramide production and partially inhibits apoptosis in doxorubicin-treated human breast carcinoma cells. Mol Pharmacol. 2001, 60 (3): 488-496.PubMed

73.

Vibet S, Goupille C, Bougnoux P, Steghens JP, Gore J, Maheo K: Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic Biol Med. 2008, 44 (7): 1483-1491. 10.1016/j.freeradbiomed.2008.01.009.CrossRefPubMed

74.

Yan W, Chen X: GPX2, a direct target of p63, inhibits oxidative stress-induced apoptosis in a p53-dependent manner. J Biol Chem. 2006, 281 (12): 7856-7862. 10.1074/jbc.M512655200.CrossRefPubMed

75.

Naiki-Ito A, Asamoto M, Hokaiwado N, Takahashi S, Yamashita H, Tsuda H, Ogawa K, Shirai T: Gpx2 is an overexpressed gene in rat breast cancers induced by three different chemical carcinogens. Cancer Res. 2007, 67 (23): 11353-11358. 10.1158/0008-5472.CAN-07-2226.CrossRefPubMed

76.

Chu FF, Esworthy RS, Chu PG, Longmate JA, Huycke MM, Wilczynski S, Doroshow JH: Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res. 2004, 64 (3): 962-968. 10.1158/0008-5472.CAN-03-2272.CrossRefPubMed

77.

Banning A, Kipp A, Schmitmeier S, Lowinger M, Florian S, Krehl S, Thalmann S, Thierbach R, Steinberg P, Brigelius-Flohe R: Glutathione peroxidase 2 inhibits cyclooxygenase-2-mediated migration and invasion of HT-29 adenocarcinoma cells but supports their growth as tumors in nude mice. Cancer Res. 2008, 68 (23): 9746-9753. 10.1158/0008-5472.CAN-08-1321.CrossRefPubMed

78.

Wilson LA, Gemin A, Espiritu R, Singh G: ets-1 is transcriptionally up-regulated by H2O2 via an antioxidant response element. FASEB J. 2005, 19 (14): 2085-2087.PubMed

79.

Hayes JD, McMahon M: NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci. 2009, 34 (4): 176-188. 10.1016/j.tibs.2008.12.008.CrossRefPubMed

80.

Warburg O: On the origin of cancer cells. Science. 1956, 123 (3191): 309-314. 10.1126/science.123.3191.309.CrossRefPubMed

Title: Ets-1 global gene expression profile reveals associations with metabolism and oxidative stress in ovarian and breast cancers
Authors: Meghan L Verschoor
Chris P Verschoor
Gurmit Singh
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Cancer & Metabolism / Issue 1/2013
Electronic ISSN: 2049-3002
DOI: https://doi.org/10.1186/2049-3002-1-17

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Monitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging

PGC-1α supports glutamine metabolism in breast cancer

LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer

Activated lymphocytes as a metabolic model for carcinogenesis

Linking vitamin B1 with cancer cell metabolism

The long and winding road to the mitochondrial pyruvate carrier

Keynote webinar | Spotlight on antibody–drug conjugates in cancer